Quantitative PET and histology of brain biopsy reveal lack of selective Pittsburgh compound-B binding to intracerebral amyloidoma

Colin Groot, MSc⁵,top, Nelleke Tolboom, MD, PhD⁴, Milos D. Ikonomovic, MD⁶,c,f, Adriaan A. Lammertsma, PhD⁴, Baayla D.C. Boon⁵,c, Frederik Barkhof, MD, PhD⁴,g, Philip Scheltens, MD, PhD¹, William E. Klunk, MD, PhD⁴,e, Annemieke J.M. Rozemuller, MD, PhD⁴, Rik Ossenkoppele, PhD⁵,c & Bart N.M. van Berckel, MD, PhD⁴

Departments of Neurology & Alzheimer Center⁴, Radiology & Nuclear Medicine⁴ and Pathology⁴, VU University Medical Center, Amsterdam, The Netherlands
Department of Neurology⁴ and Psychiatry⁴, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Geriatric Research Education and Clinical Center⁷, Veterans Administration Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA; Institutes of Neurology and Healthcare Engineering⁸, UCL, London, UK

* Correspondence to first author: Colin Groot, VU University Medical Center, de Boelelaan 1117, Amsterdam, E-mail: c.groot3@vumc.nl, tel: 0031204445240, fax: 0031204448529.
† These authors contributed equally

Running title: PiB-PET and histology in amyloidoma

Keywords: Amyloid, Histology, Positron emission tomography, case study
ABSTRACT

This case study examines selective Pittsburgh compound-B (PiB) binding to an intracerebral light-chain amyloidoma using a 90-minute dynamic $[^{11}\text{C}]\text{PiB}$-PET scan and brain biopsy tissue. Parametric non-displaceable binding potential ($\text{BP}_{\text{ND}}$) images showed negligible specific binding in the amyloidoma, while relative tracer delivery ($R_1$) was adequate. Histology of the tissue revealed strong colouring with congo-red, thioflavin-S, and X-34, indicating presence of amyloid. However, immunological staining with 6F/3D revealed absence of amyloid-$\beta$ and histofluorescence of 6-CN-PiB, a highly fluorescent derivative of PiB, was negligible. These results suggest that PiB does not detect the atypical amyloid pathology associated with an intracerebral light-chain amyloidoma.
INTRODUCTION

The development of positron emission tomography (PET) amyloid ligands such as 
\(^{11}\text{C}\)Pittsburgh compound-B (PiB) [1], have provided a non-invasive tool to assess 
amyloid-\(\beta\) (A\(\beta\)) pathology in vivo. PiB has been shown to bind strongly to fibrillar 
A\(\beta_{40-42}\) [2,3], and elevated binding of \(^{11}\text{C}\)PiB is consistently observed in patients 
with sporadic Alzheimer’s disease (AD) [4], even in very early stages of the 
disease.[5] However, several studies reported undetectable levels of \(^{11}\text{C}\)PiB PET 
retention in subjects with histologically detectable, albeit non abundant, A\(\beta\) pathology 
at time of autopsy or biopsy.[6-8] In addition, there are exceptional cases where 
\(^{11}\text{C}\)PiB retention was low in patients clinically diagnosed with AD [9-11], even in 
the presence of heavy cortical A\(\beta\) deposition in post-mortem tissue.[10] Furthermore, 
in contrast to findings in APP duplication, Swedish APP mutation and presenilin-1/2 
mutation carriers who all show levels of \(^{11}\text{C}\)PiB retention typical of late-onset AD 
[12, 13], patients with the “Arctic” APP mutation display very low \(^{11}\text{C}\)PiB retention, 
while cerebrospinal fluid levels of A\(\beta_{1-42}\) indicate presence of amyloid pathology.[14] 
An explanation for this discrepancy is offered by histological examination in “Arctic” 
APP carriers which revealed that amyloid depositions in these patients are mainly 
characterized by non-fibrillar amyloid pathology, such as protofibrils and 
oligomers.[15,16] In vitro and animal studies have shown that, at nanomolar 
concentrations administered to the living human brain, \(^{11}\text{C}\)PiB does not bind equally 

Here we present a case of a 52 year-old woman with an intracerebral light-
chain amyloidoma, a form of solitary localised, tumoral amyloidosis.[21-23] The 
diagnosis of intracerebral amyloidoma is made on the basis of histological 
examination of biopsy material, which is obtained through an invasive procedure. We
examined whether the atypical form of amyloid pathology found in intracerebral amyloidoma can also be visualized in vivo with $[^{11}\text{C}]\text{PiB-PET}$ imaging, by quantitatively assessing $[^{11}\text{C}]\text{PiB}$ binding in combination with histology from a brain biopsy performed during life.

**MATERIALS AND METHODS**

*Case description*

The 52 year-old patient was referred to the hospital because of an epileptic seizure. Her past medical history was uneventful. However, in the period leading up to the epileptic seizure, a remarkable change in personality was observed with a lack of initiative. Magnetic resonance imaging (MRI) revealed an intracranial solid neoplasm within the white matter of the right frontal lobe with both high and low intensities on T1 (Figure 1A) and FLAIR (Figure 1B). Administration of gadolinium showed a patchy enhancement of the lesion and spectroscopic examination revealed low N-acetyl aspartate and high choline levels, without lipids or lactate. All observations considered, the most probable diagnosis was an intracerebral amyloidoma.[21-23] Brain biopsy was performed to confirm this suspicion, which indeed revealed histological evidence for light-chain amyloidosis (not shown).[24] $[^{11}\text{C}]\text{PiB}$ and $[^{18}\text{F}]\text{FDG-PET}$ scans were performed two years after the diagnosis was made, and the remains of the brain biopsy were examined with additional histological stains. All procedures performed were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments. Informed consent was obtained from all individual participants included in the study.
**PET imaging**

A 90-minute dynamic \[^{11}\text{C}]\text{PiB-PET} scan protocol was performed using an ECAT EXACT HR+ scanner (CTI/Siemens, Knoxville, TN, USA). PET sinograms were corrected for dead time, tissue attenuation, decay, scatter, and randoms. Next, data was reconstructed using a standard filtered back projection algorithm and a Hanning filter with a cut-off at 0.5 times the Nyquist frequency. A matrix size of 256x256x63 was used, resulting in a voxel size of 1.2x1.2x2.4 mm and spatial resolution of approximately 7 mm full width at half-maximum at the center of the field of view. An MR image was aligned to the PET image using a mutual-information algorithm and PVE-lab, a software program that uses a probability map [25], was used to project PET data onto the structural MRI. PET data were analyzed using receptor parametric mapping with fixed efflux rate constant (RPM2) [26], generating parametric non-displaceable binding potential (BP\text{nd}) and R\text{1} images using cerebellar gray matter as reference tissue. R\text{1} represents the relative tracer delivery to the target tissue and provides an indication of flow. Furthermore, a standardized uptake value ratio (SUVr, 60-90 minute) image was generated using cerebellar gray matter as reference.

Detailed information on scanning protocol and data analysis procedures are described elsewhere.[26]

We visually assessed the amyloidoma on \[^{11}\text{C}]\text{PiB-R}\text{1}, BP\text{nd} and SUVr images. Furthermore, \[^{11}\text{C}]\text{PiB-R}\text{1}, BP\text{nd} and SUVr values were also assessed quantitatively by manually delineating the amyloidoma on MRI and calculating these parameters within the amyloidoma using an volume-of-interest (VOI) delineation tool. This VOI tool is built in-house and is used to manually draw VOI on MRI or PET images. The tool provides with a binary image of VOI that can be superimposed onto the PET scan to extract the time activity curve i.e the average activity in the VOI over time.
R₁, BPₙd and SUVr values within the volume of the amyloidoma were compared with values in a contralateral VOI, which matched the size and anatomical location of the amyloidoma (Figure 2). Finally, for the [¹⁸F]FDG PET scan we generated a SUVr image for the interval between 45-60 minute using cerebellar gray matter as the reference region.[26]

_Histology_

The tissue of the amyloidoma acquired by brain biopsy during life was examined using staining for congo-red and thioflavin-S, and immunologic staining for amyloid-β (using the monoclonal antibody 6F/3D [27]). Tissue from the amyloidoma was then additionally assessed using histofluorescence of 6-CN-PiB [28] (a highly fluorescent derivative of PiB), and X-34 [29] (a highly fluorescent derivative of congo red). As a reference, histofluorescence of 6-CN-PiB and X-34 was also assessed in frontal cortical tissue sections from an end-stage Alzheimer’s disease (AD) patient as a “positive control”.

**RESULTS**

_PET imaging_

[¹⁸F]FDG revealed a large hypometabolic region in the right frontal lobe extending beyond the location of the amyloidoma (Figure 1C). [¹¹C]PiB-PET showed low binding in cortical areas with relatively high uptake in the subcortical white matter (Figure 1D,E), similar to patterns observed in most healthy controls.[1] At the location of the amyloidoma, within the white matter, [¹¹C]PiB binding was low, as indicated by both BPₙd (Figure 1D) and SUVr (Figure 1E) images. BPₙd within the volume of the amyloidoma (8.60 mL) was 0.24, whilst BPₙd within the volume of the contralateral
VOI (6.57 mL) was 0.46. Corresponding SUVr values for amyloidoma and contralateral VOI were 1.33 and 1.44, respectively. Furthermore, the R1 image showed that tracer delivery to the amyloidoma (Figure 1F), was only slightly lower than to the contralateral VOI (0.44 and 0.56, respectively).

**Histology**

The brain biopsy tissue was clearly positive with congo-red (Figure 3A) and thioflavin-S staining (Figure 3B), indicating presence of amyloid. However, immunological staining with 6F/3D revealed that there was no amyloid-β present in the amyloidoma tissue (Figure 3C). Additional histological examinations revealed a prominent staining of amyloid with X-34, similar as in the AD “positive control” (Figure 3D,E), again indicating the presence of amyloid. However, 6-CN-PiB was at background levels compared with the robust plaque staining in the same region of the AD case (Figure 3F,G).

**DISCUSSION**

Our results indicate that [11C]PiB does not bind cerebral amyloid pathology associated with a light-chain intracerebral amyloidoma. Quantitative analysis revealed that [11C]PiB binding was negligible, despite tracer being delivered to the tissue. Furthermore, histological examination of brain biopsy tissue revealed a convincing explanation for the lack of [11C]PiB binding, as the strong colouring with congo-red, thioflavin-S and X-34 were suggestive of presence of amyloid, but the lack of 6F/3D staining indicated that there was no fibrillar amyloid-β pathology present. Furthermore, in keeping with the [11C]PiB-PET findings we observed no histofluorescence of 6-CN-PiB in the amyloidoma tissue. These results highlight that
PiB selectively binds to fibrillar Aβ pathology [2,3], and does not detect the atypical amyloid pathology found in this case of intracerebral amyloidoma.

To date, only one other study assessing accordance between in vivo amyloid imaging and histology in intracerebral amyloidoma has been published.[30] Contrary to our findings, PET imaging with [18F]Florbetapir (a different amyloid-β tracer) revealed slightly increased uptake in the region of the amyloidoma and histology showed weak staining for amyloid-β. One explanation for this discrepancy could be the heterogeneity between subjects (e.g. the absence or presence of fibrillar amyloid-β in the amyloidoma) as previous literature has described cases of intracerebral amyloidoma with histological evidence for amyloid-β (see [23] for a review). More likely, however, are factors associated with the pharmacokinetics of the different tracers. [18F] amyloid imaging ligands tend to show higher nonspecific uptake in white matter [31], which may, due to the location of the amyloidoma (within the white matter), have convoluted interpretation of results. In addition, two studies [32,33] have reported PiB detection of systemic light-chain amyloidosis. One study assessed in vivo [11C]PiB-PET binding in the heart [32] and the other assessed in vitro [3H]PiB binding in the liver and spleen [33]. However, the affinity of [3H]PiB for systemic amyloid was 448 ± 185nM in these systemic tissues; compared to 3.84 ± 0.04nM in AD brain [33]. Such low-affinity binding would not be expected to be detectable with in vivo brain PET.

Strengths of the present study include the implementation of a dynamic PET scan, which enabled us to assess tracer delivery (R₁) and [11C]PiB binding in a quantitative manner.[26] Furthermore, the study is unique in combining dynamic [11C]PiB-PET with histological examination of biopsy material. Some limitations of the present study also need to be taken into account. Localized amyloidosis,
characteristic of the amyloidoma, rarely affects the brain. Consequently, literature on this topic is sparse, with only around 30 cases having been described.[21-23, 30] This paucity of available literature, in combination with the heterogeneity in clinical and radiological presentations across cases, prevents us from making any conclusions about intracerebral amyloidoma in general.

Taken together, our results highlight the selective binding of $[^{11}C]$PiB to fibrillary Aβ and indicate that $[^{11}C]$PiB does not bind to amyloid pathology associated with light-chain intracerebral amyloidoma.

ACKNOWLEDGEMENTS

Research of the VUmc Alzheimer Center is part of the neurodegeneration research program of the Neuroscience Campus Amsterdam. The VUmc Alzheimer Center is supported by Alzheimer Nederland and Stichting VUmc fonds.

DISCLOSURES AND FUNDING

C.G., N.T., P.S., A.R. and R.O. report no disclosures. M.I. and B.v.B. report GE Healthcare consultancy and research funding. A.L. and B.v.B. are PI of a study with research grant (to institute) from Avid Radiopharmaceuticals. F.B. is supported by the NIHR-UCLH biomedical research centre. W.K. reports that GE Healthcare holds a license agreement with the University of Pittsburgh based on the technology described in this manuscript. W.K. is a co-inventor of PiB and, as such, has a financial interest in this license agreement. GE Healthcare provided no grant support for this study and had no role in the design or interpretation of results or preparation of this manuscript. Research of the VUmc Alzheimer center is part of the neurodegeneration research program of the Neuroscience Campus Amsterdam. The VUmc Alzheimer Centre is
supported by Alzheimer Nederland and Stichting VUmc fonds. All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
REFERENCES


**FIGURES**

![Fig. 1 Axial T1, FLAIR, [18F]FDG-SUVr and [11C]PiB BP_{nd}, SUVr and R_{1} PET images of the amyloidoma](image)

T1 (A) and FLAIR (B) images show the intracerebral amyloidoma in the right frontal lobe. FDG-PET (C) shows hypometabolism at the location of the amyloidoma. BP_{nd} (D) and SUVr (E) images reveal lack of PiB-binding in the amyloidoma, while the R_{1} (pseudo-flow; F) image indicates that tracer is being delivered to the amyloidoma.

FDG – Fluodeoxyglocose, FLAIR – fluid-attenuated inversion recovery, MRI – magnetic resonance imaging, PiB – Pittsburgh compound B, BP_{nd} – non-displaceable binding potential, SUVr – standardized uptake values ratio.
Fig. 2 Amyloidoma and contra-lateral volume of interest

In the left panel, the manual delineation of the amyloidoma is presented in red and the contra-lateral volume-of-interest is presented in blue. The right panel displays time-activity curves of the amyloidoma and contra-lateral volume of interest.

kBq/cc – kilobecquerel per cubic centimeter
Fig. 3 Histological staining, immunohistochemistry and histofluorescence in sections from the amyloidoma and additional histofluorescence in frontal cortex of an end-stage AD “positive control”

Congo-red (A) and thioflavin-S (B) stainings indicated presence of amyloid but 6F/3D immunohistochemistry (C) revealed no indication for Aβ pathology. Additional, X-34 histofluorescence in different sections of the biopsy material (D) again revealed presence of amyloid, similar as in the AD positive control (E). However, absence of histofluorescence with 6-CN-PiB in the amyloidoma (F), in contrast to the AD positive control (G), reveals lack of PiB binding.

Scale bar = 75 μm